Protagonist Therapeutics
PTGX
240 hedge funds and large institutions have $2.78B invested in Protagonist Therapeutics in 2024 Q3 according to their latest regulatory filings, with 78 funds opening new positions, 78 increasing their positions, 64 reducing their positions, and 24 closing their positions.
225% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 24
36% more capital invested
Capital invested by funds: $2.05B → $2.78B (+$732M)
28% more funds holding
Funds holding: 188 → 240 (+52)
22% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 64
4.13% more ownership
Funds ownership: 100.71% → 104.84% (+4.1%)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
53% less call options, than puts
Call options by funds: $2.44M | Put options by funds: $5.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$180M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$70M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$59.4M |
| 2 |
CAC
Cowen and Company
New York
|
-$34M |
| 3 |
Millennium Management
New York
|
-$33.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32.3M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$32.3M |
PTGX Hedge Fund Activity: Q3 2024 in Review
240 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2024, worth a combined $2.78B — up 36% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new PTGX positions and 24 closed out — a net gain of 54 holders — while 78 added to existing stakes and 64 trimmed.
The largest buyer was BlackRock, adding an estimated $180M. The largest seller was BVF Inc, cutting an estimated $59.4M.
- 240 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2024, up from 188 in Q2 2024.
- Funds reported $2.78B of Protagonist Therapeutics stock for Q3 2024, up 36% quarter-over-quarter.
- 78 funds opened new Protagonist Therapeutics positions in Q3 2024 and 24 closed out, a net change of +54 holders.
- The largest Protagonist Therapeutics buyer in Q3 2024 was BlackRock, an estimated $180M added.
- The largest Protagonist Therapeutics seller in Q3 2024 was BVF Inc, an estimated $59.4M sold.
Based on aggregated 13F filings for Q3 2024.